EIKN Eikon Therapeutics, Inc. Common Stock
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.07
P/S
0.00
EV/EBITDA
-0.78
DCF Value
$-2.83
FCF Yield
-409.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
43.1%
ROA
-19.1%
ROIC
-20.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-83.0M | $— |
| Q4 null | $0.00 | $-79.7M | $— |
| FY null | $0.00 | $-324.2M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.00
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.